Underwriters Laboratories
Certified


Quality Systems Regulation
Compliant


CMS Exemplary Provider


Association of Military Surgeons
United States

 


Secure Login



Regenesis Biomedical Inc.
is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant® Therapy System, indicated for the palliative treatment of post-operative pain and edema in superficial soft tissue.

Our customers include health care facilities and providers that serve patients being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Regenesis Biomedical, Inc. is a values-based company dedicated to our stakeholders: Patients, Clinicians, Shareholders, Suppliers and Employees
.


Regenesis’ core values include: having a pioneering spirit in the development of new regenerative medical products, striving for excellence in all business aspects, having respect for all people, living and working as a family unified by a common goal, applying integrity in our decision making processes, having compassion for all people, especially our patients, and dedication to improving the lives of all whom we encounter.


For more information:
Regenesis Biomedical, Inc.
1435 N. Hayden Road
Scottsdale, AZ 85257
Toll Free: 877-970-4970
Fax: 866-857-8792


News Wire

Regenesis Biomedical Earns Position on Inc. 5000 List of Fastest-Growing Companies

Department of Labor Approves Regenesis Biomedical as Equipment Supplier

Kalypto Medical and Regenesis Biomedical Enter Distribution Agreement for Novel Negative Pressure Wound Therapy System

Regenesis Biomedical Participates in the AdvaMed Value of Technology Showcase

TechAmerica Foundation Recognizes Innovation at Regenesis Biomedical

Regenesis Biomedical Supports Wound, Ostomy and Continence Nurses Society Research

Wound Care Device Patent Granted to Regenesis Biomedical

General Service Administration Awards Contract to Regenesis Biomedical

U.S. Food and Drug Administration Clears Regenesis Biomedical 510(k)

Patient Satisfaction Ratings Remain High at Regenesis Biomedical

Regenesis Biomedical Announces Charter Membership in the Alliance for Regenerative Medicine

 



Did You Know?

15% percent of diabetics will develop a chronic wound related to their disease.



Ask for the Yellow Box

 

Follow Regenesis_Bio on Twitter 

 

 

©2003 - 2010 Copyright Regenesis Biomedical Inc. All Rights Reserved